# PRDM1

## Overview
PRDM1 is a gene that encodes the PR/SET domain 1 protein, commonly referred to as Blimp-1, which is a transcriptional repressor involved in various cellular processes. Blimp-1 is characterized by its modular structure, including an N-terminal PR/SET domain, a central proline- and serine-rich region, and five C-terminal C2H2 zinc fingers, which are essential for DNA binding and protein interactions (Bikoff2009An; Morgan2012Alternative). Although it lacks intrinsic enzymatic activity, Blimp-1 recruits co-repressor proteins and histone-modifying enzymes to regulate gene expression (Bikoff2009An). It plays a pivotal role in the differentiation of B cells into plasma cells and is involved in the regulation of T cell differentiation, impacting immune responses and cellular proliferation (Di2023Exploring; Cattoretti2005PRDM1Blimp‐1). The gene's alternative splicing results in isoforms with distinct functions, influencing its role in development and disease (Morgan2012Alternative). PRDM1's activity is crucial in both normal physiological processes and pathological conditions, including various cancers and immune disorders (Küçük2011PRDM1; Casamassimi2020Multifaceted).

## Structure
The PRDM1 gene encodes the Blimp-1 protein, a transcriptional repressor with a modular structure. It comprises an N-terminal PR/SET domain, a central proline- and serine-rich region, and five C-terminal C2H2 zinc fingers (Bikoff2009An; Morgan2012Alternative). The PR/SET domain is evolutionarily conserved and resembles those found in histone lysine methyltransferases, although Blimp-1 lacks intrinsic enzymatic activity and instead recruits co-repressor proteins and enzymes that modify histone tails (Bikoff2009An). The zinc fingers are crucial for DNA binding, nuclear localization, and protein interactions, with the first two fingers recognizing a Blimp-1 consensus motif similar to the IRF interferon-stimulated regulatory element (Morgan2012Alternative).

Alternative splicing of the PRDM1 gene results in isoforms with distinct functions. The Blimp-1Δexon7 variant lacks exon 7, leading to a truncated zinc finger domain that impairs DNA binding and interaction with certain corepressors (Morgan2012Alternative). This isoform is unable to substitute for the full-length protein in embryonic development (Morgan2012Alternative). The full-length Blimp-1 preferentially binds nuclear PRMT5, while the truncated isoform interacts with cytoplasmic PRMT5 (Morgan2012Alternative).

## Function
PRDM1, also known as BLIMP1, is a transcriptional repressor that plays a critical role in the differentiation of B cells into plasma cells, which are responsible for antibody production. It functions by repressing genes such as cMYC, Pax5, and BCL6, which are essential for maintaining the B-cell phenotype and proliferation, thereby promoting the transition to plasma cells (Tunyaplin2004Direct; Cattoretti2005PRDM1Blimp‐1). This repression allows for the activation of XBP-1, which directs the synthetic and secretory machinery required for antibody production (Cattoretti2005PRDM1Blimp‐1).

In T lymphocytes, PRDM1 is induced in activated CD4+ and CD8+ cells, regulating their differentiation into effector and memory cells. It acts as a repressor in subsets of effector T cells and is involved in a feedback loop with IL-2 and STAT5, which regulates T cell expansion and differentiation (Di2023Exploring). PRDM1 can also act as a transcriptional activator in regulatory T cells by promoting H3K4 methylation at the IL10 locus (Di2023Exploring).

PRDM1 is active in the nucleus, where it binds DNA and recruits histone-modifying enzymes to silence target genes, impacting cell proliferation and apoptosis (Tunyaplin2004Direct). The balance between its isoforms, BLIMP1a and BLIMP1b, is crucial for its function, with an imbalance linked to several malignancies (Di2023Exploring).

## Clinical Significance
PRDM1, also known as BLIMP1, plays a significant role in various cancers and immune-related conditions due to its involvement in gene expression regulation. In lung cancer, reduced PRDM1 expression is linked to poor prognosis and increased metastasis, as it promotes cellular invasion and resistance to anoikis, a form of programmed cell death (Zhu2017Downregulation; Casamassimi2020Multifaceted). In breast cancer, PRDM1 is associated with a migratory phenotype in estrogen receptor alpha-negative cells, contributing to cancer progression (Casamassimi2020Multifaceted).

In hematological malignancies, PRDM1 acts as a tumor suppressor. It is frequently silenced in natural killer cell lymphomas through promoter hypermethylation and deletion, leading to impaired apoptosis and cell cycle progression (Küçük2011PRDM1). In diffuse large B-cell lymphoma, PRDM1 is genetically altered with a mutation frequency of 8.2% (Casamassimi2020Multifaceted).

PRDM1 also plays a role in gastrointestinal cancers, where its expression varies. In stomach cancer, PRDM1 is upregulated and correlates with poor prognosis, while in colon cancer, low PRDM1 expression is associated with poor survival outcomes (Hung2024Chromatin; Liu2018PRDM1). These findings highlight PRDM1's complex role in cancer biology, acting as both an oncogene and tumor suppressor depending on the context.

## Interactions
PRDM1, also known as Blimp-1, is a transcriptional repressor that interacts with various proteins to regulate gene expression. It forms complexes with Groucho family proteins, such as hGrg, TLE1, and TLE2, which are crucial for its repression activities, particularly in the regulation of IFN-β and c-myc genes (Ren1999PRDI-BF1/Blimp-1). PRDM1 also interacts with histone deacetylases HDAC1 and HDAC2, as well as G9a, to modify chromatin structure and mediate gene silencing (Morgan2012Alternative; Di2013PRDM).

In monocyte-derived dendritic cells (MO-DCs), PRDM1 interacts with NonO, a novel co-factor, to regulate the expression of the proinflammatory cytokine IL-6. This interaction is essential for PRDM1's transcriptional suppression of IL-6, as NonO binds to PRDM1-binding sites in the IL6 promoter region (Lee2020NonO). The presence of NonO is crucial for PRDM1's suppressive effect on IL-6 promoter activity, highlighting the importance of this interaction in immune response regulation (Lee2020NonO).

PRDM1 also cooperates with IRF4 for the differentiation of natural T regulatory cells and is regulated by FOXP3, indicating its involvement in complex regulatory networks within the immune system (Di2013PRDM).


## References


[1. (Casamassimi2020Multifaceted) Amelia Casamassimi, Monica Rienzo, Erika Di Zazzo, Anna Sorrentino, Donatella Fiore, Maria Chiara Proto, Bruno Moncharmont, Patrizia Gazzerro, Maurizio Bifulco, and Ciro Abbondanza. Multifaceted role of prdm proteins in human cancer. International Journal of Molecular Sciences, 21(7):2648, April 2020. URL: http://dx.doi.org/10.3390/ijms21072648, doi:10.3390/ijms21072648. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21072648)

[2. (Di2013PRDM) Erika Di Zazzo, Caterina De Rosa, Ciro Abbondanza, and Bruno Moncharmont. Prdm proteins: molecular mechanisms in signal transduction and transcriptional regulation. Biology, 2(1):107–141, January 2013. URL: http://dx.doi.org/10.3390/biology2010107, doi:10.3390/biology2010107. This article has 84 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biology2010107)

[3. (Liu2018PRDM1) Changlong Liu, Carolyn E. Banister, Charles C. Weige, Diego Altomare, Joseph H. Richardson, Carlo M. Contreras, and Phillip J. Buckhaults. Prdm1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids. Proceedings of the National Academy of Sciences, May 2018. URL: http://dx.doi.org/10.1073/pnas.1802902115, doi:10.1073/pnas.1802902115. This article has 21 citations.](https://doi.org/10.1073/pnas.1802902115)

[4. (Di2023Exploring) Erika Di Zazzo, Monica Rienzo, Amelia Casamassimi, Caterina De Rosa, Nicola Medici, Patrizia Gazzerro, Maurizio Bifulco, and Ciro Abbondanza. Exploring the putative role of prdm1 and prdm2 transcripts as mediators of t lymphocyte activation. Journal of Translational Medicine, March 2023. URL: http://dx.doi.org/10.1186/s12967-023-04066-x, doi:10.1186/s12967-023-04066-x. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12967-023-04066-x)

[5. (Cattoretti2005PRDM1Blimp‐1) Giorgio Cattoretti, Cristina Angelin‐Duclos, Rita Shaknovich, Huiping Zhou, Denong Wang, and Bachir Alobeid. Prdm1/blimp‐1 is expressed in human b‐lymphocytes committed to the plasma cell lineage. The Journal of Pathology, 206(1):76–86, March 2005. URL: http://dx.doi.org/10.1002/path.1752, doi:10.1002/path.1752. This article has 87 citations.](https://doi.org/10.1002/path.1752)

[6. (Hung2024Chromatin) Yu-Hsuan Hung, Hui-Ching Wang, Mei-Ren Pan, and Li-Tzong Chen. Chromatin remodeling-related prdm1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor. Journal of Personalized Medicine, 14(3):224, February 2024. URL: http://dx.doi.org/10.3390/jpm14030224, doi:10.3390/jpm14030224. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/jpm14030224)

[7. (Ren1999PRDI-BF1/Blimp-1) Bing Ren, Kerlen J. Chee, Tae Hoon Kim, and Tom Maniatis. Prdi-bf1/blimp-1 repression is mediated by corepressors of the groucho family of proteins. Genes &amp; Development, 13(1):125–137, January 1999. URL: http://dx.doi.org/10.1101/gad.13.1.125, doi:10.1101/gad.13.1.125. This article has 208 citations.](https://doi.org/10.1101/gad.13.1.125)

[8. (Bikoff2009An) Elizabeth K Bikoff, Marc A Morgan, and Elizabeth J Robertson. An expanding job description for blimp-1/prdm1. Current Opinion in Genetics &amp; Development, 19(4):379–385, August 2009. URL: http://dx.doi.org/10.1016/j.gde.2009.05.005, doi:10.1016/j.gde.2009.05.005. This article has 93 citations.](https://doi.org/10.1016/j.gde.2009.05.005)

[9. (Küçük2011PRDM1) Can Küçük, Javeed Iqbal, Xiaozhou Hu, Phillip Gaulard, Laurence De Leval, Gopesh Srivastava, Wing Yan Au, Timothy W. McKeithan, and Wing C. Chan. Prdm1 is a tumor suppressor gene in natural killer cell malignancies. Proceedings of the National Academy of Sciences, 108(50):20119–20124, December 2011. URL: http://dx.doi.org/10.1073/pnas.1115128108, doi:10.1073/pnas.1115128108. This article has 101 citations.](https://doi.org/10.1073/pnas.1115128108)

[10. (Tunyaplin2004Direct) Chainarong Tunyaplin, A. L. Shaffer, Cristina D. Angelin-Duclos, Xin Yu, Louis M. Staudt, and Kathryn L. Calame. Direct repression of prdm1 by bcl-6 inhibits plasmacytic differentiation. The Journal of Immunology, 173(2):1158–1165, July 2004. URL: http://dx.doi.org/10.4049/jimmunol.173.2.1158, doi:10.4049/jimmunol.173.2.1158. This article has 306 citations.](https://doi.org/10.4049/jimmunol.173.2.1158)

[11. (Zhu2017Downregulation) Zhiyan Zhu, Hao Wang, Yiliang Wei, Fanrong Meng, Zhe Liu, and Zhenfa Zhang. Downregulation of prdm1 promotes cellular invasion and lung cancer metastasis. Tumor Biology, 39(4):101042831769592, April 2017. URL: http://dx.doi.org/10.1177/1010428317695929, doi:10.1177/1010428317695929. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/1010428317695929)

[12. (Lee2020NonO) Kyungwoo Lee, Su Hwa Jang, Hong Tian, and Sun Jung Kim. Nono is a novel co-factor of prdm1 and regulates inflammatory response in monocyte derived-dendritic cells. Frontiers in Immunology, July 2020. URL: http://dx.doi.org/10.3389/fimmu.2020.01436, doi:10.3389/fimmu.2020.01436. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2020.01436)

[13. (Morgan2012Alternative) Marc A. J. Morgan, Arne W. Mould, Li Li, Elizabeth J. Robertson, and Elizabeth K. Bikoff. Alternative splicing regulates prdm1/blimp-1 dna binding activities and corepressor interactions. Molecular and Cellular Biology, 32(17):3403–3413, September 2012. URL: http://dx.doi.org/10.1128/MCB.00174-12, doi:10.1128/mcb.00174-12. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.00174-12)